Recombinant
RabMAb

Anti-VEGF Receptor 1 antibody [Y103] (ab32152)

Overview

  • Product name
    Anti-VEGF Receptor 1 antibody [Y103]
    See all VEGF Receptor 1 primary antibodies
  • Description
    Rabbit monoclonal [Y103] to VEGF Receptor 1
  • Host species
    Rabbit
  • Specificity
    Based on the antibody's immunogen sequence, it recognises 151 kDa VEGF receptor 1/Flt1, splice isoforms sFlt1 (77 kDa) and sFlt1-14 (82 kDa), and isoform 4 (61 kDa). The sequence is not present in isoforms 5-8 based on Uniprot ID P17948.
  • Tested applications
    Suitable for: WB, IHC-P, IP, IHC-Frmore details
    Unsuitable for: Flow Cyt or ICC/IF
  • Species reactivity
    Reacts with: Mouse, Rat, Human, Chinese hamster
  • Immunogen

    Synthetic peptide within Human VEGF Receptor 1 aa 1-100 (N terminal). The exact sequence is proprietary.
    (Peptide available as ab182457)

  • Positive control
    • WB: Mouse brain tissue. IHC-Fr: Mouse brain tissue.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab32152 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 151 kDa.
IHC-P 1/250.
IP 1/100.
IHC-Fr 1/250.
  • Application notes
    Is unsuitable for Flow Cyt or ICC/IF.
  • Target

    • Function
      Receptor for VEGF, VEGFB and PGF. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. Isoform SFlt1 may have an inhibitory role in angiogenesis.
    • Tissue specificity
      Mostly in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform sFlt1 is strongly expressed in placenta.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • Cellular localization
      Secreted and Cell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • EC 2.7.10.1 antibody
      • FLT 1 antibody
      • FLT antibody
      • Flt-1 antibody
      • FLT1 antibody
      • Fms like tyrosine kinase 1 antibody
      • Fms related tyrosine kinase 1 antibody
      • Fms related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) antibody
      • Fms related tyrosine kinase 1 vascular endothelial growth factor/vascular permeability factor receptor antibody
      • Fms-like tyrosine kinase 1 antibody
      • FRT antibody
      • Soluble VEGF receptor 1 14 antibody
      • Soluble VEGFR1 variant 2 antibody
      • Soluble VEGFR1 variant 21 antibody
      • Tyrosine protein kinase FRT antibody
      • Tyrosine protein kinase receptor FLT antibody
      • Tyrosine-protein kinase FRT antibody
      • Tyrosine-protein kinase receptor FLT antibody
      • Vascular endothelial growth factor receptor 1 antibody
      • Vascular endothelial growth factor vascular permeability factor receptor antibody
      • Vascular permeability factor receptor 1 antibody
      • Vascular permeability factor receptor antibody
      • VEGFR 1 antibody
      • VEGFR-1 antibody
      • VEGFR1 antibody
      • VGFR1_HUMAN antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human abdominal aortic aneurysm (AAA) wall tissue sections labeling VEGF Receptor 1 with ab32152 at 1/100 dilution.

      Resected aortic tissues were immersed in 10% neutral buffered formalin for at least 24 h for immunohistochemical staining. Tissue sample was embedded in paraffin; 4 µm sections were cut and mounted onto MAS-coated slides. The sections were deparaffinized, dehydrated, and boiled in a pressure cooker in 0.01 M citric acid buffer (pH 6.0) for 20 min. The sections were washed with phosphate-buffered saline and incubated with 3% H2O2 in absolute methanol for 5 min to inhibit any endogenous peroxidase activity. Sections were preincubated with 3% normal goat serum for 20 min to minimize nonspecific binding to VEGF Receptor 1, and incubated with ab32152 at 4°C overnight in a moist chamber. The section was washed with phosphate-buffered saline and then incubated with the appropriate secondary antibody for 30 min at room temperature. Staining was visualized with Vector DAB, and tissue section was then counterstained with hematoxylin.

    • Immunohistochemistry (PFA perfusion fixed frozen sections) analysis of mouse brain tissue section (15 days old wild-type mouse embryonic brain, 16 micron) labeling VEGF Receptor 1 with ab32152 at 1/300 dilution.

      Tissue was fixed with formaldehyde and permeabilized with Triton X-100. Heat mediated antigen retrieval was performed using 10mM citrate buffer, pH 6. A polyclonal donkey anti-Rabbit IgG (H+L) (Alexa Fluor® 488) secondary antibody was used at 1/500 dilution. 

      See Abreview

    • Anti-VEGF Receptor 1 antibody [Y103] (ab32152) at 1/10000 dilution + mouse brain tissue

      Predicted band size: 151 kDa
      Observed band size: 180 kDa (why is the actual band size different from the predicted?)

    References

    This product has been referenced in:
    • Jeong BY  et al. Rab25 augments cancer cell invasiveness through a ß1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Exp Mol Med 50:e435 (2018). Read more (PubMed: 29371698) »
    • Lu HJ  et al. Mechanism of MicroRNA-708 Targeting BAMBI in Cell Proliferation, Migration, and Apoptosis in Mice With Melanoma via the Wnt and TGF-ß Signaling Pathways. Technol Cancer Res Treat 17:1533034618756784 (2018). Read more (PubMed: 29466930) »

    See all 98 Publications for this product

    Customer reviews and Q&As


    After looking into our data for ab32152, I found the following abReview, which was submitted by another researcher using ab32152 in immunocytochemistry. According to the researcher's protocol (link below) permeabilization was not necessary, which ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up